Endogenous peptide YY and neuropeptide Y inhibit colonic ion transport, contractility and transit differentially via Y₁ and Y₂ receptors.

Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print Cited Medium: Internet ISSN: 1476-5381 (Electronic) Linking ISSN: 00071188 NLM ISO Abbreviation: Br J Pharmacol Subsets: MEDLINE

Publication: London : Wiley
Original Publication: London, Macmillian Journals Ltd.

Colon/*physiology ; Gastrointestinal Transit/*physiology ; Neuropeptide Y/*metabolism ; Peptide YY/*metabolism ; Receptors, Neuropeptide Y/*metabolism; Aged ; Animals ; Colon/metabolism ; Female ; Gastrointestinal Transit/genetics ; Humans ; Intestinal Mucosa/metabolism ; Intestinal Mucosa/physiology ; Ion Transport/physiology ; Male ; Mice ; Mice, 129 Strain ; Mice, Inbred C57BL ; Mice, Knockout ; Muscle Contraction/physiology ; Muscle, Smooth/metabolism ; Muscle, Smooth/physiology ; Neuropeptide Y/genetics ; Peptide YY/genetics ; Receptors, Neuropeptide Y/antagonists & inhibitors ; Receptors, Neuropeptide Y/genetics

Background and Purpose: Peptide YY (PYY) and neuropeptide Y (NPY) activate Y receptors, targets under consideration as treatments for diarrhoea and other intestinal disorders. We investigated the gastrointestinal consequences of selective PYY or NPY ablation on mucosal ion transport, smooth muscle activity and transit using wild-type, single and double peptide knockout mice, comparing mucosal responses with those from human colon.
Experimental Approach: Mucosae were pretreated with a Y₁ (BIBO3304) or Y₂ (BIIE0246) receptor antagonist and changes in short-circuit current recorded. Colonic transit and colonic migrating motor complexes (CMMCs) were assessed in vitro and upper gastrointestinal and colonic transit measured in vivo.
Key Results: Y receptor antagonists revealed tonic Y₁ and Y₂ receptor-mediated antisecretory effects in human and wild-type mouse colon mucosae. In both, Y₁ tone was epithelial while Y₂ tone was neuronal. Y₁ tone was reduced 90% in PYY⁻/⁻ mucosa but unchanged in NPY⁻/⁻ tissue. Y₂ tone was partially reduced in NPY⁻/⁻ or PYY⁻/⁻ mucosae and abolished in tetrodotoxin-pretreated PYY⁻/⁻ tissue. Y₁ and Y₂ tone were absent in NPYPYY⁻/⁻ tissue. Colonic transit was inhibited by Y₁ blockade and increased by Y₂ antagonism indicating tonic Y₁ excitation and Y₂ inhibition respectively. Upper GI transit was increased in PYY⁻/⁻ mice only. Y₂ blockade reduced CMMC frequency in isolated mouse colon.
Conclusions and Implications: Endogenous PYY and NPY induced significant mucosal antisecretory tone mediated by Y₁ and Y₂ receptors, via similar mechanisms in human and mouse colon mucosa. Both peptides contributed to tonic Y₂-receptor-mediated inhibition of colonic transit in vitro but only PYY attenuated upper GI transit.
(© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.)

Physiol Behav. 2008 Oct 20;95(3):271-81. (PMID: 18692080)
Eur J Neurosci. 2008 Jul;28(1):173-80. (PMID: 18616565)
Am J Physiol Gastrointest Liver Physiol. 2007 Mar;292(3):G930-8. (PMID: 17158255)
Peptides. 2002 Feb;23(2):403-7. (PMID: 11825656)
Biochim Biophys Acta. 2005 Aug 1;1751(1):33-44. (PMID: 15978877)
Gynecol Oncol. 2002 Oct;87(1):143-5. (PMID: 12468356)
Neurogastroenterol Motil. 1997 Jun;9(2):109-16. (PMID: 9198086)
Regul Pept. 1999 Aug 31;83(1):11-9. (PMID: 10498339)
Peptides. 2010 Apr;31(4):671-5. (PMID: 19925840)
Gastroenterology. 1996 May;110(5):1491-5. (PMID: 8613054)
Gastroenterology. 2010 Feb;138(2):659-70 670.e1-2. (PMID: 19782081)
Cell Metab. 2010 Jun 9;11(6):532-42. (PMID: 20519124)
J Pharmacol Exp Ther. 2004 Dec;311(3):1154-62. (PMID: 15308651)
Diabetologia. 2006 Jun;49(6):1360-70. (PMID: 16680491)
Nucleic Acids Res. 2006;34(21):6126-36. (PMID: 17085477)
Am J Health Syst Pharm. 2007 Jun;64(12):1265-73. (PMID: 17563048)
Am J Physiol Gastrointest Liver Physiol. 2003 Dec;285(6):G1139-46. (PMID: 12919938)
Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G564-72. (PMID: 14630643)
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15034-9. (PMID: 17848507)
Peptides. 2001 Mar;22(3):445-52. (PMID: 11287100)
J Neurochem. 2008 May;105(3):641-52. (PMID: 18088353)
Behav Brain Res. 2009 Oct 12;203(1):97-107. (PMID: 19397935)
Regul Pept. 1993 Dec 10;49(2):133-44. (PMID: 7907802)
Pflugers Arch. 1988 Nov;413(1):38-42. (PMID: 2464161)
Neurogastroenterol Motil. 2000 Aug;12(4):343-52. (PMID: 10886676)
Lancet. 1990 Jun 30;335(8705):1555-7. (PMID: 1972488)
Eur J Pharmacol. 1999 Jun 11;374(1):85-91. (PMID: 10422644)
Brain Res. 2005 May 17;1044(1):127-31. (PMID: 15862798)
Regul Pept. 1984 Jul;8(4):261-6. (PMID: 6548568)
J Physiol. 1988 Apr;398:65-80. (PMID: 3392683)
Br J Pharmacol. 2009 Nov;158 Suppl 1:S1-254. (PMID: 19883461)
Gastroenterology. 2009 Apr;136(4):1328-38. (PMID: 19138686)
Neurosci Lett. 1997 May 23;227(3):212-4. (PMID: 9185688)
Cell Tissue Res. 1996 Apr;284(1):39-53. (PMID: 8601295)
Eur J Pharmacol. 1985 Dec 10;119(1-2):47-52. (PMID: 3866691)
Cell Tissue Res. 2009 May;336(2):179-89. (PMID: 19326148)
Neurogastroenterol Motil. 2000 Feb;12(1):33-41. (PMID: 10652114)
Gut. 1987 Feb;28(2):166-70. (PMID: 3557189)
Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G887-96. (PMID: 15637177)
Auton Neurosci. 2007 Apr 30;133(1):76-85. (PMID: 17140858)
Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G144-57. (PMID: 20413719)
Am J Physiol Gastrointest Liver Physiol. 2010 Jan;298(1):G45-56. (PMID: 19892938)
J Pharmacol Exp Ther. 2006 Oct;319(1):20-30. (PMID: 16807358)
Diabetes. 2005 Oct;54(10):2988-94. (PMID: 16186403)
Br J Pharmacol. 2003 Jun;139(4):863-71. (PMID: 12813010)
Br J Pharmacol. 2002 Mar;135(6):1505-12. (PMID: 11906964)
Eur J Pharmacol. 1999 Nov 19;384(2-3):R3-5. (PMID: 10611450)
BMC Complement Altern Med. 2005 Sep 17;5:18. (PMID: 16168064)
Anat Histol Embryol. 2003 Feb;32(1):21-8. (PMID: 12733269)
J Auton Nerv Syst. 1997 Dec 11;67(3):168-75. (PMID: 9479668)
Gastroenterology. 2007 May;132(5):1912-24. (PMID: 17484884)
Br J Pharmacol. 1998 Oct;125(3):549-55. (PMID: 9806339)
Gut. 2000 Mar;46(3):370-5. (PMID: 10673299)

BB/E527098/1 United Kingdom BB_ Biotechnology and Biological Sciences Research Council; 079291/Z/06/Z United Kingdom WT_ Wellcome Trust

0 (Neuropeptide Y)
0 (Receptors, Neuropeptide Y)
0 (neuropeptide Y-Y1 receptor)
0 (neuropeptide Y2 receptor)
106388-42-5 (Peptide YY)

Date Created: 20110405 Date Completed: 20120320 Latest Revision: 20220129

20250114

PMC3188896

10.1111/j.1476-5381.2011.01401.x

21457230